This bill reauthorizes funding for the C.W. Bill Young Cell Transplantation Program and the national cord blood inventory through 2031.
John "Jack" Reed
Senator
RI
The Stem Cell Therapeutic and Research Reauthorization Act of 2026 extends critical funding and support for life-saving medical programs through 2031. This legislation ensures the continued operation of the C.W. Bill Young Cell Transplantation Program and maintains the national cord blood inventory. These measures are essential for sustaining vital resources used in stem cell therapies and research.
The Stem Cell Therapeutic and Research Reauthorization Act of 2026 locks in federal support for the systems that match patients with bone marrow and umbilical cord blood donors. By amending the Public Health Service Act, the bill allocates $33,009,000 annually from fiscal year 2027 through 2031 for the C.W. Bill Young Cell Transplantation Program. This isn’t just a budget line item; it’s the infrastructure that powers the national registry, helping doctors find genetic matches for people fighting leukemia, lymphoma, and other life-threatening blood disorders. For a family waiting on a miracle, this bill ensures the 'search' button keeps working.
The heart of this legislation is the C.W. Bill Young Cell Transplantation Program, which acts as a massive, high-tech matchmaking service for patients who don’t have a compatible donor in their own family. Section 2 of the bill specifically increases the annual funding to over $33 million, a jump from the previous $31 million threshold. Think of it like maintaining a vital piece of national infrastructure; just as we fund highways to move goods, this funds the data and logistics required to move biological material from a donor in one state to a patient in an operating room halfway across the country.
Beyond bone marrow, the bill focuses heavily on the national cord blood inventory. Section 3 extends the authorization for this inventory through 2031, ensuring that cord blood—which is rich in blood-forming stem cells—remains collected, stored, and available for treatment. For a new parent deciding to donate cord blood, this provision ensures there is a stable, federally backed system ready to receive and utilize that gift. By extending these programs for another five years, the bill provides the medical community and research institutions with the long-term certainty they need to manage these inventories without the threat of a sudden shutdown or funding gap.